<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23306">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01813513</url>
  </required_header>
  <id_info>
    <org_study_id>IDX-06A-004</org_study_id>
    <nct_id>NCT01813513</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idenix Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idenix Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential for a pharmacokinetic (PK) drug-drug
      interaction between simeprevir and IDX719 and to assess the safety and tolerability when the
      two drugs are administered alone and in combination for up to 14 days in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Pharmacokinetic measures of plasma drug exposure (AUCss and Cmax) of IDX719 and simeprevir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Up to 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- Safety and tolerability of IDX719 and simeprevir, alone and in combination, using key safety parameters (adverse events, physical examinations, vital signs, ECGs and standard laboratory safety tests).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 healthy volunteers Days 1-7 = IDX719 150 mg once daily and Days 8-14 = IDX719 150 mg once daily + simeprevir 150 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 Healthy Volunteers Days 1-7 = simeprevir 150 mg once daily  and Days 8-14 = IDX719 150 mg once daily  + simeprevir 150 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Healthy Volunteers Days 1-14 = IDX719 150 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX719</intervention_name>
    <description>50 mg tablets X 3, once daily</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simeprevir</intervention_name>
    <description>150 mg capsule X 1, once daily</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Read and signed the written informed consent form (ICF) after the nature of the study
             has been fully explained.

          -  All subjects of childbearing potential must have agreed to use a double method of
             birth control (one of which must be a barrier) from Screening through at least 90
             days after the last dose of the study drug

        Exclusion Criteria:

          -  Pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 26, 2013</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>antiviral drugs</keyword>
  <keyword>liver</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
